Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Wilson WH, et al. Among authors: habermann tm. Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20. Nat Med. 2015. PMID: 26193343 Free PMC article. Clinical Trial.
Diffuse large B-cell lymphoma.
Habermann TM. Habermann TM. Clin Adv Hematol Oncol. 2005 Nov;3(11):suppl 4-5. Clin Adv Hematol Oncol. 2005. PMID: 16491628 Review. No abstract available.
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM. Micallef IN, et al. Among authors: habermann tm. Cancer. 2006 Dec 15;107(12):2826-32. doi: 10.1002/cncr.22342. Cancer. 2006. PMID: 17099879 Free article. Clinical Trial.
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.
Simpson L, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Ristow KM, Johnston PB, Markovic SN, Micallef IN, Porrata LF, Witzig TE. Simpson L, et al. Among authors: habermann tm. Leuk Lymphoma. 2007 Jul;48(7):1332-7. doi: 10.1080/10428190701435259. Leuk Lymphoma. 2007. PMID: 17613762
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Wiernik PH, et al. Among authors: habermann tm. J Clin Oncol. 2008 Oct 20;26(30):4952-7. doi: 10.1200/JCO.2007.15.3429. Epub 2008 Jul 7. J Clin Oncol. 2008. PMID: 18606983 Clinical Trial.
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.
Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S, Geyer SM, Cozen W, Chanock SJ, Cerhan JR. Habermann TM, et al. Blood. 2008 Oct 1;112(7):2694-702. doi: 10.1182/blood-2007-09-111658. Epub 2008 Jul 16. Blood. 2008. PMID: 18633131 Free PMC article.
452 results